Finding Pulmonary Arterial Hypertension-Switching to Offense to Mitigate Disease Burden
- PMID: 35234810
- PMCID: PMC9040384
- DOI: 10.1001/jamacardio.2022.0011
Finding Pulmonary Arterial Hypertension-Switching to Offense to Mitigate Disease Burden
Conflict of interest statement
Conflicts of Interest
B.A.M., Deerfield Corporation (beyond the scope of this work); Actelion Sciences (beyond the scope of this work); Patent #9,605,047 (beyond the scope of this work), PCT/US2019/059890 (beyond the scope of this work), PCT/US2020/066886 (beyond the scope of this work). M.H.: Acceleron, Altavant, Bayer, Janssen, Merck and MorphogenIX (beyond the scope of this work).
Figures
References
-
- Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010. Jul 13;122(2):156–63. - PubMed
-
- Hoeper MM, Pausch C, Grunig E, et al. Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. J Heat Lung Transpl 2020;39:1435–1444. - PubMed
-
- Kwon J-M, Kim K-H, Medina-Inojosa J, et al. Artificial intelligence for early prediction of pulmonary hypertension using electrocardiography. J Heart Lung Transpl 2020;39:805–814. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
